-Data support plans to initiate a Phase 3 study of ivacaftor in people with CF who have a residual function mutation- BOSTON--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results